Skip to main content

Table 1 Comparison of baseline characteristics and concomitant use drugs between the two groups

From: Effects of 6-month eicosapentaenoic acid treatment on postprandial hyperglycemia, hyperlipidemia, insulin secretion ability, and concomitant endothelial dysfunction among newly-diagnosed impaired glucose metabolism patients with coronary artery disease. An open label, single blinded, prospective randomized controlled trial

 

Non-EPA group (n = 53)

EPA group (n = 54)

P value

Age (y.o)

68.9 ± 8.8

67.8 ± 9.1

0.49

Sex (male, n, %)

43 (81.1 %)

44 (81.5 %)

0.84

Coronary risk factor

 Hypertension (n, %)

49 (92.5 %)

48 (88.9 %)

0.76

 Dyslipidemia (n, %)

53 (100 %)

54 (100 %)

0.99

 Smoking (n, %)

4 (7.5 %)

5 (9.3 %)

0.98

Concomitant use drug

 Statin (n, %)

44 (83.0 %)

46 (85.2 %)

0.97

 Calcium channel blocker (n, %)

30 (56.6 %)

27 (50.0 %)

0.62

 ACEI/ARB (n, %)

35 (66.0 %)

40 (74.1 %)

0.49

  1. Values are presented as number (%) or mean ± standard deviation, as indicated
  2. ACEI angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840